Skip to content
10-Q

Quarterly Report

Intra-Cellular Therapies, Inc.

0001628280-24-044196

← back to feed
Filed
Oct 30, 2024 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2024 · Oct 28, 2024 106.02M sh
Shares Diluted Q3 2024 · Sep 30, 2024 105.77M sh
Shares Diluted Q3 2024 · Sep 30, 2024 102.14M sh
Shares Diluted Q3 2024 · Sep 30, 2023 96.14M sh
Shares Diluted Q3 2024 · Sep 30, 2023 95.75M sh
Capex Q3 2024 · Sep 30, 2024 $749K
Capex Q3 2024 · Sep 30, 2023 $268K
Operating Cash Flow Q3 2024 · Sep 30, 2024 −$60.1M
Operating Cash Flow Q3 2024 · Sep 30, 2023 −$122.14M
Cash And Equivalents Q3 2024 · Sep 30, 2024 $464.31M
Cash And Equivalents Q3 2024 · Dec 31, 2023 $147.77M
Cash And Equivalents Q3 2024 · Sep 30, 2023 $99.4M
Stockholders Equity Q3 2024 · Sep 30, 2024 $1.14B
Stockholders Equity Q3 2024 · Jun 30, 2024 $1.14B
Stockholders Equity Q3 2024 · Mar 31, 2024 $599.5M
Stockholders Equity Q3 2024 · Dec 31, 2023 $591.42M
Stockholders Equity Q3 2024 · Sep 30, 2023 $600.68M
Stockholders Equity Q3 2024 · Jun 30, 2023 $607.09M
Stockholders Equity Q3 2024 · Mar 31, 2023 $627.61M
Stockholders Equity Q3 2024 · Dec 31, 2022 $656.07M
Current Liabilities Q3 2024 · Sep 30, 2024 $166.11M
Current Liabilities Q3 2024 · Dec 31, 2023 $123.55M
Total Liabilities Q3 2024 · Sep 30, 2024 $179.62M
Total Liabilities Q3 2024 · Dec 31, 2023 $136.87M
Current Assets Q3 2024 · Sep 30, 2024 $1.27B
Current Assets Q3 2024 · Dec 31, 2023 $667.8M
Total Assets Q3 2024 · Sep 30, 2024 $1.32B
Total Assets Q3 2024 · Dec 31, 2023 $728.3M
Eps Diluted Q3 2024 · Sep 30, 2024 −$0.25
Eps Diluted Q3 2024 · Sep 30, 2024 −$0.57
Eps Diluted Q3 2024 · Sep 30, 2023 −$0.25
Eps Diluted Q3 2024 · Sep 30, 2023 −$1.16
Eps Basic Q3 2024 · Sep 30, 2024 −$0.25
Eps Basic Q3 2024 · Sep 30, 2024 −$0.57
Eps Basic Q3 2024 · Sep 30, 2023 −$0.25
Eps Basic Q3 2024 · Sep 30, 2023 −$1.16
Rd Expense Q3 2024 · Sep 30, 2024 $66.82M
Rd Expense Q3 2024 · Sep 30, 2024 $165.84M
Rd Expense Q3 2024 · Sep 30, 2023 $41.55M
Rd Expense Q3 2024 · Sep 30, 2023 $129.37M
Net Income Q3 2024 · Sep 30, 2024 −$26.32M
Net Income Q3 2024 · Sep 30, 2024 −$57.79M
Net Income Q3 2024 · Jun 30, 2024 −$16.22M
Net Income Q3 2024 · Mar 31, 2024 −$15.25M
Net Income Q3 2024 · Sep 30, 2023 −$24.26M
Net Income Q3 2024 · Sep 30, 2023 −$111.1M
Net Income Q3 2024 · Jun 30, 2023 −$42.78M
Net Income Q3 2024 · Mar 31, 2023 −$44.05M
Operating Income Q3 2024 · Sep 30, 2024 −$38.85M
Operating Income Q3 2024 · Sep 30, 2024 −$87.52M
Operating Income Q3 2024 · Sep 30, 2023 −$29.71M
Operating Income Q3 2024 · Sep 30, 2023 −$125.28M
Revenue Q3 2024 · Sep 30, 2024 $175.38M
Revenue Q3 2024 · Sep 30, 2024 $481.63M
Revenue Q3 2024 · Sep 30, 2023 $126.17M
Revenue Q3 2024 · Sep 30, 2023 $332.27M